Castle Biosciences (CSTL) Return on Capital Employed (2019 - 2026)

Castle Biosciences has disclosed Return on Capital Employed across 8 years of filings, most recently posting 6.47% for Q1 2026.

• Return on Capital Employed for Q1 2026 came in at 6.47%, down 359.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 6.47% (down 359.0% YoY), and the FY2025 annual result was 8.8%, down 1076.0% from the prior year.
• Return on Capital Employed came in at 6.47% for Q1 2026 at Castle Biosciences, up from 8.53% in the prior quarter.
• In the past five years, Return on Capital Employed ranged from a high of 1.83% in Q4 2024 to a low of 24.73% in Q2 2023.
• The 5-year median for Return on Capital Employed is 9.89% (2024), against an average of 10.89%.
• Across the five-year window, Return on Capital Employed sank 1175 bps in 2022 and surged 2136 bps in 2024, its largest moves.
• Castle Biosciences' Return on Capital Employed stood at 17.49% in 2022, then climbed by 2 bps to 17.12% in 2023, then surged by 111 bps to 1.83% in 2024, then sank by 566 bps to 8.53% in 2025, then grew by 24 bps to 6.47% in 2026.
• The last three Return on Capital Employed figures came in at 6.47% (Q1 2026), 8.53% (Q4 2025), and 7.01% (Q3 2025), per Business Quant data.